This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	BCR-ABL tyrosine kinase	<i>In vitro</i> and mouse studies identified a pyrazolo[3,4- <i>d</i>]pyrimidine that could help treat CML with the T315I resistance mutation in BCR-ABL. In mouse myeloid cells that express T315I mutant Bcr-Abl, compared with cells expressing wild-type Bcr-Abl, the molecule showed increased cytotoxicity. In mice grafted with myeloid cells that expressed T315I mutant Bcr-Abl, the inhibitor decreased tumor volume by more than 50% compared with vehicle. Next steps could include testing the inhibitor in additional animal models for CML.	Patent and licensing status unavailable	Radi, M. <i>et al. J. Med. Chem.</i> ; published online June 7, 2013; doi:10.1021/jm400233w Contact: Maurizio Botta, University of Siena, Siena, Italy e-mail: botta.maurizio@gmail.com Contact: Silvia Schenone, University of Genoa, Genoa, Italy e-mail: schensil@unige.it
<i>SciBX</i> 6(27); doi:10.1038/scibx.2013.679 Published online July 18, 2013				